Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: Imaging circuitry may include circuits for implementing current or voltage mode feature extraction in the analog domain. The imaging circuitry may include pixels configured to generate pixel values. The pixel values may then be weighted using adjustable weighting circuits to generate corresponding weighted pixel values. The adjustable weighting circuits may be selectively coupled to the floating diffusion node in each pixel. The weighted pixels values may then be combined to obtain an output neuron voltage for at least one layer in a neural network. Performing feature extraction in the analog domain for each layer of results in the neural network saves power and area by avoiding the need to move data around to conventional digital memories.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: Aspects of the invention provide a method and system for synchronizing a transceiver and a framer in an optical transmission network. Subsequent to achieving synchronization of an inbound data stream, an internal framer may be adapted to inform a downstream device such as a full framer, that synchronization has already been attained. Accordingly, the downstream device may not need to perform resynchronization of the inbound data and can immediately start processing the inbound data. Advantageously, the internal framer may provide expedited error checking, handling and reporting prior to receipt of the data by the downstream device.

Abstract: In general, in one aspect, the disclosure includes a description of a method that includes accessing network traffic metering data and controlling power consumption of individual ones of a set of network processor processing engines based on the metering data.

Abstract: Aspects of the invention provide a method and system for synchronizing a transceiver and a framer in an optical transmission network. Subsequent to achieving synchronization of an inbound data stream, an internal framer may be adapted to inform a downstream device such as a full framer, that synchronization has already been attained. Accordingly, the downstream device may not need to perform resynchronization of the inbound data and can immediately start processing the inbound data. Advantageously, the internal framer may provide expedited error checking, handling and reporting prior to receipt of the data by the downstream device.